Clinical Study
Effectiveness of Glycyrrhizinic Acid (Glizigen) and an Immunostimulant (Viusid) to Treat Anogenital Warts

José Domínguez Gómez,1 Ramón Daniel Simón,1 Alfredo Abreu Daniel,1 and Hana Zelenkova2

1 Hospital Clínico Quirúrgico Comandante Manuel Fajardo, Havana, Cuba
2 Private Clic of dermatovenerologie, Svidnik, Slovakia

Correspondence should be addressed to Hana Zelenkova, zelenkova@vl.sk

Received 21 March 2012; Accepted 3 May 2012

Academic Editors: E. Nagore and R. A. Schwartz

Copyright © 2012 José Domínguez Gómez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Genital warts are benign proliferations of skin and mucosa caused by the human papillomavirus infection. These viruses do not have any acute signs or symptoms, just the slow growth of lesions that can be subclinical for long periods of time [1]. They are a group of DNA viruses that belong to the Papovaviridae family, they are nonenveloped, and they cause all kinds of warts and a great deal of tropism on different parts of the body [2]. Up to 150 different types have been identified and around 40 of these infect the anogenital tract in men and women [3]. They are classified as being either high or low oncogenic risk types, the latter includes types 6 and 11, which are responsible of the appearance of condylomata in more than 90% of the cases [4].

Genital warts is one of the most common sexually transmitted diseases in the world, its incidence rate has increased in the last three decades; 600 million individuals are thought to be infected and 190 million with clinical infection. There are not any official statistics on the prevalence of the HPV infection in Latin America [5]. In Cuba, 83,521 cases were reported in the period 1990–2003 [6].

It is transmitted through sexual intercourse, trauma with contaminated material, contact with surfaces that are infected with the virus, and, occasionally, vertical transmission (trans placental) or perinatal (contact with the birth canal). The incubation period is between 2 to 9 months [7–9]. The disease is not as contagious in the early stages [10–12].

Lesions are located on the penis, vulva, scrotum, perineum, and the perianal area; the cervix, urethra, anus, mouth; and also in the conjunctiva, the nose, and the larynx [7]. They vary in appearance; some are pinpoint papules, others are cauliflower-like masses. They can be red, pink, or skin colour [13]. Depending on the size and the anatomical location they can be painful, friable, or itchy. Even though
they are usually asymptomatic, they do have a considerable psychological impact on the sufferer.

The diagnosis is based on the clinical examination. The use of acetic acid (3–5%) improves the detection of these lesions, biopsy [7], detecting low serum antibody titres, immunohistochemical analysis of the HPV structural proteins (confirmatory method) by DNA hybridization technique and finding the nucleic acid of a virus (DNA or RNA) or the capsid protein as a definitive diagnosis [11].

Current treatment involves the physical destruction of the infected cells, but the fact that there are many types of treatment goes to show that none of these are uniformly effective or directly antiviral. As the preferred treatment involves eliminating the visible wart, there is no evidence that shows that the existing treatment available eradicates the HPV infection, reduces the infectivity, or modifies the natural history of the infection [11].

The nonsurgical treatment includes the interferon (topical, intralesional, or systematic), podophillin, and imiquimod topical, and the most used (more experience) are podophyllin and the trichloroacetic acid and cryosurgery although significant differences were not found when these were used to treat external anogenital warts.

Alternative therapy is part of the medical arsenal available to treat many of the diseases that we are faced with on a daily basis. By using the aforementioned knowledge and that obtained from other recent studies, Catalysis Laboratories has developed a product called GLIZIGEN. One of its main active ingredients is glycyrrhizinic acid, which is a substance found in the Glycyrrhiza glabra root, commonly known as “sweet root”, that was used way back in ancient Egypt and China to treat respiratory infections and as an anti-inflammatory. Modern-day research has demonstrated its anti-inflammatory activity, its antiulcerative and antiviral effect. The former (0.1 g in 100 mL of the vehicle) interacts with viral proteins, which according to the stage of the viral infection can lead to the inactivation of extracellular free virus particles, the prevention of the intracellular decapsulation of infectious particles, and the deterioration of the assembling capacity of the structural components of the virus.

Its beneficial effects are enhanced by molecular activation that considerably improves the biological activity of the antioxidizing molecules and that of all other molecules that contain carboxyl groups in their structure; it can also make antiviral activity up to 10,000 times as effective.

Clinical studies carried out at dermatovenerology and gynecology clinics confirm its effectiveness. It does not produce any complications in pregnant women; it's 100% effective in the early stages of the disease and 90% in relapse cases; it is very well tolerated, it does not cause skin irritation, and it is quite innocuous. No interactions with other pharmacological preparations have been documented. One of these is Viusid, a food supplement that has been especially designed to help balance and stimulate the functions of the immune system. It contains antiviral agents, antioxidants, and anti-free radicals that are essential for our health as they boost the defenses of the immune system and strengthen the whole organism.

Given the prevalence of this STI, its biological and psychological repercussions, the lack of effective medicine, and the new therapeutic possibilities that provide us with alternative types of treatment, a study was organised so as to evaluate how successful the combination of Glizigen-Viusid is in treating external genital warts.

### 2. Method

A prospective experimental clinical trial was performed with the help of Catalysis Laboratories (Madrid, Spain). The sample consisted of 100 patients who were divided up into 2 groups, each having 50 individuals who were selected according to the inclusion criteria and by simple random sampling.

#### 2.1. Method of Use for the Medicine

The lesions of all the patients were measured with a ruler and the area of skin

| Age groups (years) | Glizigen | Podophyllin |
|-------------------|----------|-------------|
| 15 to 24          | 29       | 30          |
| 25 to 34          | 10       | 10          |
| 35 to 44          | 3        | 5           |
| 45 to 54          | 2        | 3           |
| ≥55               | 4        | 2           |
| Total             | 48       | 50          |

The lesions of all the patients were measured with a ruler and the area of skin

*Table 1: Distribution of patients according to their ages.*
affected was determined. Up to 10 cm² was the limit set for members of both groups.

Members of the control group were administered podophyllin once a week for 6 weeks. At the end of this period, if the lesions had not disappeared, the treatment was changed and the subsequent results were not included in the clinical trial, those obtained during the follow-up period were not either because the patients were considered to have abandoned the clinical trial.

Members of the group that was treated with Glizigen were given written instructions on how many sprays of the product had to be applied at the out-patients unit (once spray is equal to two small squirts) according to the area of skin that was affected: 1 to 3.9 cm², 3 times a day; from 4 to 6.9 cm², 4 times a day; 7 to 10 cm², 5 times a day, for 8 weeks. After this period, the treatment was reviewed to see whether it should be combined or replaced by a more conventional type of treatment that depended on the specific patient, just like the procedure followed with podophyllin, in which case they were considered to have abandoned the clinical trial. Moreover, a 30 mL dose of Viusid (syrup) was administered every 8 hours, each day, during the treatment. The patients were told to take it after meals, dissolving it in drinking water, fruit juice, or milk.

Two patients from the group treated with Glizigen decided, on their own free will, to leave the clinical trial, so 48 patients managed to complete the treatment. All the members from the control group completed the treatment.

The lesions were photodocumented at the start and at the end of the treatment. A data collection model was used (see annex) that showed the general data about the patients and the disease. The results were kept on an Excel database and were statistically processed with the EPIDAT 3.1. software.

3. Results

On analysing the distribution of patients according to their age, the predominant group was clearly that consisting of patients aged between 15 and 24 (Table 1). There were no significant differences with regard to the gender-related distribution in either of the products used (Figure 1).

Figure 2 shows the response to the treatment; a good response to both products was observed. However, the best response to both treatments was seen in the last two weeks of using them (Figures 3 and 4).

On evaluating the correlation between curing the skin lesion and the affected area on diagnosis, less than 5 cm²...
At the start

After 8 weeks of treatment

Figure 5: Photodocumentation. Lesions on the back of the penis.

At the start

After 8 weeks of treatment

Figure 6: Photodocumentation. Lesions on the glans penis.

Table 2: Correlation between the cured lesion and the affected area of skin.

| Area affected by the lesions | Glizigen | Podophyllin |
|-----------------------------|----------|-------------|
|                             | Cured    | Not cured   | Cured    | Not cured |
| <5 cm²                      | 38       | 5           | 36       | 10        |
| >5 cm²                      | 4        | 1           | 2        | 2         |
| Total                       | 42       | 6           | 38       | 12        |
| CI (95%)                    | $\chi^2 = 0.0319$ | $P = 0.8583$ | $\chi^2 = 0.4344$ | $P = 0.5098$ |

Table 3: Discomfort associated with the treatment.

| Symptoms  | Glizigen | Podophyllin |
|-----------|----------|-------------|
|           | No.  | %   | No.  | %   |
| Burning   | 3    | 6   | 15   | 30  |
| Pain      | 1    | 2   | 4    | 8   |
| Itching   | 5    | 10  | 4    | 8   |
| None      | 39   | 82  | 27   | 54  |
| Total     | 48   | 100 | 50   | 100 |

The evolution of the lesions after applying the medicine is shown in the photos (Figures 5 and 6).

4. Discussion

In general, response to both treatments was good, although that of Glizigen was slightly better than that of podophyllin. An analysis was carried out to see whether this difference was statistically significant for a 95% confidence interval; however the corresponding results showed it was not. International studies have produced varied efficacy responses to podophyllin that range from between 44% and 76% [1, 4, 7, 19, 24–26] and they have had good results with high rates of healing with Glizigen, although the percentage of efficacy has not been determined [27–31].

Given the maximum time period established to use both products, in weeks (8 for Glizigen and 6 for podophyllin), more patients whose lesions did actually heal within this period did so in the last two weeks. In the studies analysed, we did not find any specific results that were similar to those shown in our graphs, although the time limit set for the lesions to heal in the population mean for each treatment was the same.

Even though the affected area of skin was measured in cm² in our clinical trial, which is different from the measuring unit of this variable used in other published studies, they do coincide in some respects. The majority of patients from

of the skin in more than 84% of the members of both groups was affected (Table 2). With regards to discomfort mentioned by the patients during the treatment period, Glizigen was seen to be tolerated better (Table 3).
most of the series analysed were reported to have less than 10 lesions (mainly small ones), which is understood as being a similarity. This still has to be proved by further research, [1, 7, 10, 19, 25, 26] but it could be due to the fact that there are plenty of qualified personnel available, the medical culture of the patients themselves, and because the lesions are very noticeable, especially for members of the sexually active population, so they go to the doctor before the affected area gets worse. In turn, an analysis was carried out to see whether the size of the affected area was associated with the response to the treatment. The results of such showed that these variables were independent too, as shown in the corresponding table.

The results obtained when using Glizigen coincide with those obtained by other authors using this medicine [19, 31, 32].

Out of all the findings, the penis was the most affected genital organ in men. Almost half the patients had suffered from the lesions for 1 to 4 months, which coincides with the findings of the international reports [10, 19, 25, 26, 33]. We can conclude the following.

1. Using Glizigen together with Viusid was effective in treating the external anogenital warts.
2. The variables concerning age, gender, anatomical location, and the area affected by the lesions coincide with what has been reported by other researchers.
3. There was a good clinical response to both treatments.
4. The combined Glizigen-Viusid treatment was better than the treatment with podophyllin.
5. The effectiveness and innocuousness of Glizigen combined with Viusid in the treatment of this disease are confirmed.

References

[1] R. L. Douglas and J. A. E. Warts, Dermatologia en Medicina General, Editorial Médica Panamericana, Buenos Aires, Argentina, 5ta edición, 2001.
[2] Z. L. Papiloma, http://www.facmed.unam.com.
[3] Consenso de Papiloma Virus Humano (HPV) y Herpes Simple Virus (HSV) Genital, http://www.sad.org.ar.
[4] M. Menéndez, M. D. L. A. Hernández, O. A. vela de Oro, and A. Torres Chávez, “Actualización de la terapéutica del papiloma humano. Terapia convencional,” Revista Cubana de Medicina, vol. 43, no. 1, pp. 34–41, 2004.
[5] O. E. F. Wincheids and A. L. González, Condiloma Acuminado. Guías Clínicas en Atención primaria 2003, 3 (33), http://www.fisterra.com.br.
[6] Dirección Nacional de Estadísticas. MINSAP, Cuba, 2004.
[7] Centers for Disease Control and Prevention, “Guidelines for treatment of sexually transmitted diseases,” Morbidity and Mortality Weekly Report, vol. 51, no. RR06, pp. 1–80, 2002.
[8] P. E. Castle, S. Wacholder, A. T. Lorincz et al., “A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women,” Journal of the National Cancer Institute, vol. 94, no. 18, pp. 1406–1414, 2002.
[9] E. De Clercq, “Therapeutic potential of HPMPC as an antiviral drug,” Reviews in Medical Virology, vol. 5, pp. 85–96, 1993.
[10] M. Favre, N. Ramoz, and G. Orth, “Human papillomaviruses: general features,” Clinics in Dermatology, vol. 15, no. 2, pp. 181–198, 1997.
[11] Centers for Disease Control and Prevention, Sexually transmitted diseases treatment guidelines 2002/MMWR, 51(No. RR-6):[53-57]http://www.cdc.gov/STD/treatment/.
[12] E. Van Cutsem, R. Snoeck, M. Van Ranst et al., “Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cystosine,” Journal of Medical Virology, vol. 45, no. 2, pp. 230–235, 1995.
[13] Y. H. Li, X. H. Gao, C. D. He, Z. Guomei, Z. X. Don, and H. D. Chan, “Detection of human papillomavirus and response to oral arabinoid ethylster in 2 cases of Darier disease,” Archives of Dermatology, vol. 137, pp. 695–696, 2001.
[14] F. X. Bosch, M. M. Manos, N. Muñoz et al., “Prevalence of human papilloma virus in cervical cancer: a worldwide perspective,” Journal of the National Cancer Institute, vol. 87, no. 11, pp. 796–802, 1995.
[15] D. Calisto and F. Arcangeli, “Topical cidofovir for condylomata acuminata of the genitalia in a 3-year-old child,” Journal of the American Academy of Dermatology, vol. 49, no. 6, pp. 1192–1193, 2003.
[16] N. Muñoz, F. X. Bosch, S. de Sanjosé et al., “Epidemiologic classification of human papillomavirus types associated with cervical cancer,” The New England Journal of Medicine, vol. 348, no. 6, pp. 518–527, 2003.
[17] F. T. Al-Gurairi, M. Al-Waiz, and K. E. Sharquie, “Oral zinc sulphate in the treatment of recalcitrant viral warts: randomized placebo-controlled clinical trial,” British Journal of Dermatology, vol. 146, no. 3, pp. 423–431, 2002.
[18] R. J. Signore, “Candida immunotherapy of warts,” Archives of Dermatology, vol. 137, pp. 1250–1251, 2001.
[19] M. A. Munigua, Eficacia del ácido glicirrítico activado, con relación al nitrógeno líquido, y a la combinación de ambos, en el tratamiento del condiloma acuminado en pacientes atendidos en el Centro Nacional de Dermatología [Tesis de Especialista], Universidad Nacional Autonoma de Nicaragua, UNAN-Managua, 2006.
[20] Y. Soto, M. Mune, and A. Goicolea, “Aplicación de la técnica de reacción en cadena de la polimerasa para la detección de secuencias de Papilomavirus humano,” Revista Cubana de Medicina Tropical, vol. 50, no. 3, pp. 191–198, 1998.
[21] G. J. N. Sanabria, A. M. Mérida, S. V. Medina, and P. G. Valdés, 2004, Prevalencia del Papiloma Humano en el cuello uterino. Pinar del Río, http://www.conganat.org/7congreso/trabajo.asp?idtrabajo=495.
[22] R. Á. Sintes, Editorial Ciencias Médicas, vol. 2, no. 23, pp. 414–417, 2001.
[23] Ministerio de Salud Pública Colectivo de Autores, Infecciones de Transmisión Sexual, pautas para su tratamiento, Ministerio de Salud Pública, Ciudad Habana, Cuba, 2004.
[24] G. von Krogh, C. J. N. Lacey, G. Gross, R. Barrasso, and A. Schneider, "European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts," Sexually Transmitted Infections, vol. 76, no. 3, pp. 162–168, 2000.
[25] L. Acevedo AS, Eficacia de la Podofilina, el Ácido tricloroacético y la Criocirugía en el Tratamiento de las Verrugas Genitales [Tesis de Especialista], ISCM-H. Facultad Coman-dante Manuel Piti Fajardo, Ciudad Habana, Cuba, 2005.
[26] C. Miracco, N. Palummo, D. Lavergne, A. Nyongo, P. Tosi, and E.-M. de Villiers, “Malignant melanoma: search for human
papillomavirus,” *Archives of Dermatology*, vol. 137, pp. 826–827, 2001.

[27] B. A. Luis, *Estudio multicéntrico, prospectivo, abierto, controlado, sobre la eficacia, la seguridad clínica y la tolerabilidad local de la administración repetitiva (t.i.d.) por 5 días del ácido glicirrízico activado (Epigen) en pulverizaciones locales a pacientes cursando con herpes genital*, Hospital General de México, Servicio de Infectología, Mexico City, México, 1997.

[28] I. I. Bogatyreva, *Experience in Usage of EPIGEN at Treatment of Papilloma Virus Infection of the Urogenital Duct*, Central Science—Research Institute of Dermatovenereal Diseases, City of Moscow, 2008.

[29] O. Martin-Crevillente, *Report on the Results of the Tests with the Product Epigen (Laboratories Cheminova International, S.A., Madrid). Evaluate the Effectiveness and the Tolerance of the Antiviral Preparation Epigen in Women with Papillomavirus Infection*, Ginecologic Center, “Salud y Mujer”, Madrid, Spain.

[30] A. Espinoza and L. Barragán, *Estudio longitudinal, prospectivo, abierto, sobre la evaluación de la efectividad, la seguridad clínica y la tolerabilidad local de la administración repetitiva (q.i.d.) por 10 días del ácido glicirrízico activado (Epigén) en pulverizaciones locales a pacientes cursando con infección por virus del papiloma humano (HPV) a nivel del cérvix uterino*, Clínica de Detección y Tratamiento de Displasias, Universidad de Guadalajara, Mexico City, México, 2004.

[31] H. Zelenková, A. Nejdková, E. Škutilová, M. Urbáni, D. Švecová, and J. Cabalová, “Preparations containing glycyrrhizic acid employed in dermatovenerelogic practice. Conclusions of an international multicentre study,” *Dermatologia Kliniczna*, vol. 7, no. 3, pp. 135–139, 2005.

[32] G. Andrews and A. Domonkos, “Enfermedades viricas,” in *Tratado de Dermatología*, p. 486, Editorial Médica Panamericana, 5ta edition, 2004.

[33] A. Rook, D. S. Wilkinson, F. J. Ebling, R. H. Champion, and J. Burton, *Textbook of Dermatology*, Blackwell Scientific, London, UK, 5th edition, 1992.